AUTO7

AUTO7 is an investigational **autologous anti-PSMA CAR T-cell therapy** being developed for prostate cancer, particularly metastatic castration-resistant prostate cancer. It is designed to recognize **prostate-specific membrane antigen** on tumor cells through a humanized CAR construct and has been described as a multi-modular engineered T-cell product intended to improve persistence, tumor killing, and resistance to the immunosuppressive tumor microenvironment. Public descriptions indicate that the construct incorporates additional functional modules including a safety switch and features intended to counter inhibitory signaling such as TGF-beta and SHP2-mediated suppression. The program has been associated with **Autolus** and originated from work linked to **University College London**; available public information suggests the asset has remained at the **preclinical or early development** stage rather than reaching regulatory approval.